Curriculum Vita

**Name:** Kimberly Ann Yonkers, M.D.

**School:** Yale University School of Medicine

**Education:** B.A., Amherst College, 1979

 M.D., Columbia College of Physicians and Surgeons, 1986

**Career/Academic Appointments:**

1986-1987 Intern in Medicine, St. Luke's Roosevelt Hospital, N.Y.

1987-1990 Resident in Psychiatry, McLean Hospital, Belmont, MA

1990-1992 Attending in Psychiatry McLean Hospital and Massachusetts General Hospital

1990-1992 Fellow in Neuroscience, Harvard Medical School

1990-1992 Assistant Clinical Psychiatrist, Brigham & Women's Hospital, Division of Psychiatry

1990-1992 Instructor, Department of Psychiatry, Harvard Medical School, Boston, MA

1992-1998 Assistant Professor, Department of Psychiatry and Obstetrics & Gynecology, The University of Texas Southwestern Medical Center, Dallas, TX

1998-1999 Associate Professor, Department of Psychiatry and Obstetrics & Gynecology, The University of Texas Southwestern Medical Center, Dallas, TX

1999-2009 Associate Professor, Department of Psychiatry, Yale School of Medicine

2005-2009 Associate Professor, Department of Obstetrics and Gynecology and Reproductive Sciences, Yale School of Medicine

1999-present Instructor, Division of Chronic Disease Epidemiology, Yale School of Epidemiology and Public Health

2009-present Professor, Department of Psychiatry, Yale School of Medicine

2009-present Professor, Department of Obstetrics and Gynecology and Reproductive

 Sciences, Yale School of Medicine

2011-present Professor, Division of Chronic Disease Epidemiology, Yale School of Epidemiology and Public Health

**Administrative Positions:**

2015-present Director of Research, Yale New Haven Hospital Division, Department of Psychiatry

2014-present Director of Research, Psychological Medicine Service, Department of Psychiatry

2000-present Director, Center for Wellbeing of Women and Mothers

2016- Deputy Director for Faculty Development and Research, Yale New Haven Hospital Division, Department of Psychiatry

**Board Certification**: American Board of Psychiatry & Neurology, Psychiatry, 1991(Grandfathered into future)

**Professional Honors or Recognition**:

A) International/National/Regional

2015 Academy of Psychosomatic Medicine Wayne Katon Research Award

2001-2015 Best Doctors – USA

2001-2007 Best Doctors – New York Metro Area

2005 NARSAD Mid-Career Investigator Award

1999 Texas State Psychiatric Physicians Research Award

1996-1998 Best Doctors – Dallas, Texas

1994-1996 NARSAD Young Investigator Award

1992 New Investigator Award, New Clinical Drug Evaluation Unit

1990-1991 Dupont Warren Fellow, Harvard University

1988-1990 Sol W. Ginsberg Fellow, Group for Advancement of Psychiatry

1984-1986 William F. Grupe Scholar, College of Physicians and Surgeons

1981 Macy Scholar for Research in Biology, Columbia University

1979 Magna Cum Laude, Amherst College

1979 President's Award, Amherst College

1979 Simpson Fellow, Amherst College

B) University

2008-2012 Albert S. McKern Fund Committee Member

2010-2012 Senior Allotment Committee Member

2015- Senior Appointments and Promotion Committee Member

**Grant History**:

**CURRENT:**

Doris Duke Foundation

**Fund to Retain Clinical Scientists**

P.I. Robert Sherwin, M.D.

Role: Co-Director

01/01/2016-12/31/2021

Total Costs: $2,700,000

*The goal of this grant is to provide supplemental and flexible funds to clinician-scientists to help them maintain productivity while they face extraprofessional demands.*

National Cancer Institute

**Progesterone Augmentation for Smoking Cessation in Women**

R21 198187

P.I. Kimberly Yonkers, M.D. and Mehmet Sofuoglu, M.D., Ph.D.

9/1/2015-8/31/2017

Total Costs: $457,875

*This study will manipulate the hormonal milieu by adding progesterone to the follicular phase of the menstrual cycle in order to enhance women’s response to nicotine replacement therapy.*

Centers for Disease Control

**Prenatal Substance Use Screening Measures**

R21 DP006082-01

P.I. Kimberly Yonkers, M.D.

07/25/2015-06/24/2017

Total Costs:$1,199,984

*This study would test the validity and reliability of 6 screening measures for substance use and misuse in pregnancy.*

National Institute of Drug Abuse

**Three Strategies for Implementing Motivational Interviewing on Medical Inpatient Units**

R01 DA034243

P.I.s: Kimberly Yonkers, MD and Steve Martino, PhD

07/01/2012 – 06/30/2017

Total Costs: $3,724,655

*The goal of this project is to compare the success of 3 strategies geared to implementation of motivational interviewing. The interviewing techniques would be provided by physician assistants in the general medical units of Yale New Haven Hospital*

National Institute of Drug Abuse

**Project START: Screening to Augment Referral to Treatment**

R01 DA027194

P.I.s.: Kimberly Yonkers, MD and Steve Martino, PhD

08/01/2010 – 07/31/2016

Total Costs: $3,541,448

*This proposal conducts a randomized clinical trial which compares two SBIRTS, delivered either by a trained nurse or by computer, to usual care (a control condition). As part of this trial, we will include outcomes that allow us to assess the cost effectiveness of these three conditions.*

R01 CA195654-01

NIH/NCI

**Harnessing the Power of Technology: MOMBA for Postpartum Smoking**

P.I. Smith

Role: Co-Investigator

9/19/14 – 8/31/18

0.6 Calendar Months

Total Costs: $2,249,000

*This study proposes to conduct a randomized clinical trial evaluating the efficacy of a smart phone application for reduction in smoking among postpartum women.*

**Past :**

National Institute of Drug Abuse

**Economic Evaluation of Drug Abuse Treatment and HIV Prevention Services for Pregnant Women**

R01 DA 025555

P.I.: Jennifer Ruger, PhD (U Penn)

Sub. P.I. Kimberly Yonkers, M.D.

01/21/2009-12/31/2015

Total Costs: $1,900,000

*This evaluation proposes to conduct an economic evaluation of a behavioral approach with pregnant women to decrease substance abuse, reduce HIV risk behavior, and improve post natal outcomes.*

National Institute of Drug Abuse

**Progesterone for Postpartum Cocaine Relapse**

R21 DA029914

P.I.: Kimberly Yonkers, MD and Mehmet Sofuoglu, PhD

09/01/2010 – 07/31/2013

Total Costs: $455,125

*This double-blind, randomized, placebo controlled trail will obtain preliminary data on the efficacy of oral micronized progesterone for postpartum women with a history of cocaine dependence or abuse.*

National Institute of Mental Health

**Symptom-Onset Antidepressant Treatment for PMDD**

R01 MH072955

P.I.: Kimberly Yonkers, MD

04/01/2007-02/29/2013

Total Costs: $1,607,980

*The goal of this project is to determine whether initiation of sertraline use on the day patients’ symptoms begin is an effective treatment for PMDD.*

National Institute of Child Health and Human Development

**The National Children’s Study, Litchfield County, CT**

HHSN275200800022C

P.I.: Michael Bracken, PhD

09/26/2008-010/25/2012

Total Costs: ~ $1,000,000

*Examines the effects of environmental influences on children’s health and development.*

Role: Co-Investigator

National Institute of Child Health and Human Development

**The National Children’s Study, New Haven County, CT**

HHSN26700700028C

P.I.: Michael Bracken, PhD

09/28/2007-09/27/2012

Total Costs: $3,500,000

*Examines the effects of environmental influences on children’s health and development.*

Role: Co-Investigator

Connecticut Department of Public Health

**Community-based Education on Perinatal Depression**

P.I.: Kimberly Yonkers, MD

Total Costs: $50,000

11/01/2009-09/30/2010

*The goal of this grant is to train workers at the Connecticut Department of Children and Families and local obstetrical practices about screening and treatment of perinatal depression.*

National Institute of Drug Abuse

**Psychosocial Research to Improve Drug Treatment in Pregnancy**

R01 DA019135

P.I.: Kimberly Yonkers, MD

09/20/2004-08/31/2010

Total Costs: $2,356,970

The goal is to assess the effectiveness of a relapse prevention strategy for hazardous substance use in pregnant women.

National Institute of Child Health and Human Development

**Effects of Perinatal Depression on Preterm Delivery and Low Birth Weight**

R01 HD045735

P.I.: Kimberly Yonkers, MD

09/01/2004 – 06/30/2010

#### Total Costs: $4,847,516

*The goal of this grant is to determine the impact of depression and its pharmacological treatment on risk of low birth weight and preterm delivery.*

National Association for Research in Schizophrenia and Depression

Independent Investigator Award

**A Controlled Study of SSRI Exposure in Neonates**

P.I.: Kimberly Yonkers, MD

Total Costs: $99,087

09/15/2005-09/14/2009

*The goal of this study is to determine whether there is a higher rate of perinatal complications among offspring exposed to SSRIs in utero.*

Connecticut Dept of Public Health

CT Department of Public Health

# Perinatal Depression Provider Consultation Line

Catalog # 2008-0182 / PND

P.I.: Kimberly Yonkers, MD

Total Costs: $80,000

02/01/2008-12/31/2008

*The goal of this project is to develop and implement a consultative telephone support line for health care providers whose clients are experiencing perinatal depression or providers who have questions about how to treat depression in pregnancy or the postpartum period.*

Robert Wood Johnson Foundation

**Identifying and Treating Maternal Depression In Underserved, Minority Women in a Pediatric**  **Primary Care Setting**

P.I.: Carol Weitzman, PhD

Total Costs: $100,000

12/01/2006-11/30/2008

*The goal of this project is to identify depressed mothers whose children have screened positive for behavioral health problems during routine pediatric well-child visits. We will then randomize depressed mothers to receive either 1) short-term group CBT treatment and psychopharmacologic intervention and intensive case management or 2) intensive case management alone.*

Role: Co-Investigator

National Institute of Mental Health

**Treating PMS/PMDD: Research vs. Clinical Reality**

R21 MH62379 01A1

P.I.: Kimberly Yonkers, MD

#### Total Costs: $430,000

07/01/2001-06/30/2006

*The major goal of this study is to evaluate the efficacy of PMS/PMDD treatments in a primary care ob/gyn setting.*

CT Department of Public Health

# State Grants for Perinatal Depression

Contract Log #2006-0293

P.I.: Kimberly Yonkers, MD

Total Costs: $79,901

12/15/2005 – 12/31/2006

*In conjunction with the State of Connecticut Department of Public Health, the purpose of the project is to: (1) increase public awareness and reduce the stigma of perinatal depression; (2) increase the number of women and their families who seek information and treatment for depression; and (3) increase the number of health care providers who are able to recognize the signs and symptoms of perinatal depression.*

Ethel F. Donaghue Women’s Health Investigator Program at Yale

#### A Comparison of Calcium and Fluoxetine as PMDD Treatments

P.I.: Kimberly Yonkers, MD

#### Total Costs: $168,000

*The major goal of this project is to compare the effectiveness, especially among primary care ob-gyn patients, of fluoxetine and calcium for the treatment of moderate to severe premenstrual syndrome (PMS).*

National Institute of Mental Health

## Postpartum Mood Disorders: A Multimedia Tool Kit

SBIR-HHSN278200443097C

P.I.: McElaney

Total Costs: $24,000

11/01/2004-12/31/2005

*The goal of this grant is to develop a DVD video intervention for postpartum mood disorders for professional staff training and continuing education.*

Role: Site Principal Investigator

U.S. Department of Health and Human Services:

Health Resources and Services Administration, Maternal and Child Health Bureau

**Improving Women’s Health Through Screening & Intervention for Depression During and Around the Time of Pregnancy**

CATALOG # 93-926L

P.I.: Kimberly Yonkers, MD

#### Total Costs: $739,200

07/01/2001-06/30/2005

*The major goal of this project is to enhance depression screening and treatment services within the inner-city New Haven community of women seeking prenatal and post-partum care. This is an enhancement to the Healthy Start Initiative.*

National Institute of Mental Health

#### Detection and Treatment of Postpartum Depression

K08 MH01648

P.I.: Kimberly Yonkers, MD

#### Total Costs: $833,140

09/01/1999-12/31/2004

*This is a Mentored Research Clinical Scientist Development Award (MRSCA). The major goal of this project is to advance my knowledge regarding effectiveness research, particularly as it relates to women with mood disorders.*

**Past Clinical Trials:**

Lilly Research Laboratories

**A Comparison of Antidepressant Treatment in Women with and Without Postpartum Onset of Major Depressive Disorder**

F1J-US-X043

P.I.: Kimberly Yonkers, MD

06/01/2007-12/31/2009

Total Costs: $52,810

*The goal of this study is to evaluate the efficacy and safety of the treatment of postpartum onset and non-postpartum onset major depressive disorder with the dual reuptake inhibitor duloxetine.*

Wyeth Pharmaceuticals

**A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of a Combination of Levonorgestrel and Ethinyl Estradiol in a Continuous Daily Regimen in Subjects with Premenstrual Dysphoric Disorder (PMDD)**

PROTOCOL 0858A-316-NA

P.I.: Kimberly Yonkers, MD

Total Costs: $233,090

01/01/2006-06/01/2007

0.12 Calendar Months

*The primary purpose of this research is to evaluate the efficacy and safety of this continuous dose oral contraceptive preparation compared with placebo in treating the symptoms of premenstrual dysphoric disorder (PMDD).*

**Courses Attended:**

July 2016-Current: Executive Leadership in Academic Medicine

Aug 2015-July 2016: Yale Medical Group Emerging Leaders Executive Education Program, Part I

Apr 12-15, 2016: Yale School of Management Women’s Leadership Program

Sept 2014-May 2015: The OpEd Project Public Voices Program at Yale

**COURSES Taught:**

Jan-Mar, 2017: How to Write a Manuscript, Psychosomatic Medicine Residents, Fellows and Faculty

Mar-Apr, 2014: How to Write a Manuscript, Psychosomatic Medicine Residents & Fellows

Jan-Feb, 2014: Research Methods in Psychiatry, Psychosomatic Medicine Residents & Fellows

Mar-Apr, 2013: Research Methods in Psychiatry, Psychosomatic Medicine Residents & Fellows

**INVITED SPEAKING ENGAGMENTS, PRESENTATIONS, SYMPOSIA & WORKSHOPS NOT AFFILIATED WITH YALE**:

5/13/2016: International Society of Psychosomatic Obstetrics and Gynecology and 20th Congress of the Psychosomatic SEGO Section. Malaga Spain, “Symptom Expression of PMDD with Contraceptive Use”

5/13/2016: International Society of Psychosomatic Obstetrics and Gynecology and 20th Congress of the Psychosomatic SEGO Section. Malaga Spain, “Screening for Substance Use in Pregnancy”

5/13/2016: International Society of Psychosomatic Obstetrics and Gynecology and 20th Congress of the Psychosomatic SEGO Section. Malaga Spain, “Symptom-Onset Sertraline Treatment for PMDD”

4/1/2016: Harvard University “A Master Class”, Boston Massachusetts, “The Role of Antidepressants in the Life Cycle of Women”

3/22/2016: Grand Rounds, Icahn School of Medicine at Mount Sinai, NY NY, “Psychiatric Illness, Psychiatric Treatment and Birth Outcomes.”

11/12/15: Annual Meeting of the Academy of Psychosomatic Medicine, New Orleans, Louisiana, Wayne Katon Research Award Lecture, “Affective Disorders, Antidepressant Treatment and Birth Outcomes”

09/18/15: 42nd Annual Regional Perinatal Symposium, Syracuse, NY, Keynote Speaker, “Management of Depression in Pregnancy” and concurrent session, “Abstinence and Relapse in Perinatal Women with Addiction”

4//24/2015: Harvard University “A Master Class”, Boston Massachusetts, “The Role of Antidepressants in the Life Cycle of Women”

1/14/2015: Grand Rounds University of Miami Miller School of Medicine, Miami Florida. “To Treat or Not to Treat, that is the Question: Use of Antidepressants in Pregnancy”

6/6/2014: Annual Meeting of the American Psychiatric Association, New York, NY, Distinguished Psychiatrist Lecture, “Psychiatric Illness, Psychiatric Treatment and Pregnancy Outcomes”

4/14/2014: Harvard University Psychopharmacology Update, Boston, Massachusetts, “Management of Psychiatric Disorders in Pregnancy”

9/5/2014: Grand Rounds University of South Florida, Tampa Florida, “Risk vs Benefit in Use of Antidepressants n Pregnancy”

12/11/2013: Grand Rounds Stony Brook University Medical Center, Stony Brook. N.Y., ” Update on Premenstrual Dysphoric Disorder”

10/10-12/2013: Colombia Conference of Psychiatry 2013, Cartegna, Colombia, Visiting Lecturer, “PMDD: Rationale for a new DSM-5 Diagnosis”, “Pharmacological Treatment of Pregnant and Postpartum Women”, “Gender, Race, Ethnicity and Culture in DSM-5”

7/18/2013: Grand Rounds, Middlesex Hospital, Middletown, CT, “Major Depressive Disorder in Pregnancy”

6/6/2013: March of Dimes Annual Meeting for the Media, New York, New York, “Psychiatric Illness and Treatment in Pregnancy”4//22/ 2012:, North American Society for Psychosocial Ob-Gyn, Providence, RI, “Risk vs Benefits in the Care of Pregnant Women”

4//21/ 2012: Harvard University “A Master Class”, Boston Massachusetts, “Women’s Mental Health Issues”

3/16/2012: University of Wisconsin Psychiatric Update, Madison Wisconsin, “Management of Mood Disorders in Pregnancy”

1/26/2012, Grand Rounds, Bridgeport Hospital, Bridgeport, CT, “Depression in Pregnancy and After Delivery”

11/30/2011: Yale Substance Abuse Seminar, New Haven, CT, “ Hazardous Substance Abuse in Pregnancy”

4/30/2011: Harvard Medical School Master Class in Psychopharmacology, Boston, MA, “PMS, Perinatal and Postpartum Psychopharmacology”

4/27/2011: Framingham, MA, New England Obstetrical and Gynecological Society, “Recognition and Treatment of Depression in Pregnancy and After Delivery”

4/7/2011: Mercy College, New Rochelle, NY, Fetal, Child and Maternal Health - New Research and Policies conference, “Maternal Mental Health”

11/30/ 2010: Greenwich Hospital, Greenwich, CT, Women’s Health Initiative Lecture Series, “When Blue is Not Your Best Color”

10//20/2010: Ridgefield, CT, First Leir Conference on Perinatal Health, “What, Who and When of Perinatal Depression”, “Detection of Depression and Treatment Engagement”, “Benefits and Risks of Treatment”

10/18/2010: National Institutes of Health, Office of Women’s Health Research, Bethesda, Maryland, “Clinical Experiences Enrolling Pregnant Women with Depression”

10/17/2009: Keynote, Ontario Women's Mental Health Research Conference, Toronto, Canada, “Course of Depression in Pregnancy”

9//29/ 2009: Centers for Disease Control, Atlanta, Georgia, “Best Practices in Screening for Mental Health and Substance Use Disorders”

5//19/2009: Connecticut Children’s Medical Center, Hartford, CT, Hartford, Connecticut,“Maternal Depression Screening in Primary Care Pediatrics”

5/14/2009: Grand Rounds, New York University, New York, NY, “Traumatic Stress in Pregnancy”

3/7/2009: Dialogues in Psychopharmacology, New York, New York “Management of Depression in Pregnancy”

2/27/2009: Grand Rounds, University of St Louis Department of Obstetrics and Gynecology, “Depression and Antidepressant Treatment in Pregnancy”

5/16/2008: Baystate Annual Psychiatry Conference: Depression, Holyoke, MA, “Depression and its Treatment in Perinatal Women”

4/5/2008: National Alliance of Mental Health Annual Conference, New Haven, CT, “Antidepressant Use in Pregnancy”

12/12/2007: Grand Rounds, State University of New York School of Medicine at Stonybrook, Stonybrook, NY Department of Psychiatry, “Managing Mood Disorders During Pregnancy”

5/25/2007: Western Massachusetts Psychiatric Society, Springfield, MA, “Update on Managing Mood Disorders During Pregnancy”

5/2/2007: Visiting Professorship and Grand Rounds, State University of New York School of Medicine at Stonybrook, Stonybrook, NY, Department of Obstetrics and Gynecology, “Power versus Precision: The Impact of Depression and Antidepressant Treatment on Birth Outcomes”

4/25/2007: University of Michigan Grand Rounds, Ann Arbor, MI, “Depressed and Pregnant: Lessons from the Healthy Start Depression Initiative”

2/28/2007: Visiting Professorship and Grand Rounds, University of Massachusetts, Worcester, MA, Department of Obstetrics and Gynecology, “Depression and the Treatment of Depression in Pregnancy”

12/7/2006: Holbrook Hospital Grand Rounds, Westport, CT, “Update on Antidepressant Use in Pregnancy”

11/30/2006: Southern Gynecological Association, Dallas, TX, “A Tale of Two Treatments for PMDD”

5//16/2006: Depression Summit, State of Connecticut, Middletown, CT, “Depression in Pregnancy and Postpartum”

3/29/2006: Senate Staff Briefing, Washington, D.C., “Importance of Mood Disorders in Women”

2/27/2006: Boston Obstetrical Society, Boston, MA, “PMDD*-*New Therapeutic Approaches*”*

3/4/2006: Long Island Jewish Hospital Annual Mood Disorders Conference, Garden City, NY, “Management of Mood Disorders in Women”

2/2/2006: Hartford Hospital Grand Rounds, Hartford, CT, “Detection and Management of Pregnant Women with Depression”

19/19-26/2005: World Psychiatric Association, Amsterdam, PMS and PMDD

10/8/2005: University of Cincinnati Continuing Medical Education, Cincinatti, OH, The Annual Psychopharmacology Update: The Psychopharmacology of Populations with Co-Existing Conditions, “Depression in Women”

6/17/2005: Baylor Health Care System, 13th Annual Wells Leadership and Scientific Session, Dallas, TX, “Recognition and Treatment of Premenstrual Dysphoric Disorder”

6/15/2005: UCONN Health Partners, West Hartford, CT, “Mood Disorders in Pregnancy, Diagnosis and Risk Factors”

6/4-6/2005: Medical University of SC: Institute of Psychiatry, Charleston, SC, “Perinatal Depression: When is it more than the Blues?”

5/5/2005: Baystate Health System Office of Continuing Education, Holyoke, MA, Psychopharmacology Seminar, “Treatment of Depression in Women”

4/14-15/2005: University of Pittsburgh School of Medicine, Western Psychiatric Institute & Clinics Visiting Professorship Program, Pittsburgh, PA, “Screening for Depression in Pregnancy: Evaluation of the New Haven Healthy Start Program”

 2/10-12/2005: North American Society for Psychosocial Obstetrics and Gynecology, Continuing Medical Education Annual Meeting, Coronado CA, “Update on PMDD”

4/15/2004: UCONN Health Center, Farmington, CT, “Women’s Presence in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)”

2/28/2004: North Shore-LIJ Health System, Garden City, NY, “Update on the Pharmacotherapy of Mood Disorders”

11/15/2003: Montefiore Medical Center, Bronx, NY, Autumn in NY Conference

11/5/2003: Baystate Health System, Holyoke, MA, Annual Women’s Health Conference

**Peer-Reviewed Presentations & Symposia Given at Meetings Not Affiliated With Yale**

6/18/2014: American Society of Clinical Psychopharmacology Annual Meeting, Hollywood, Florida“Progesterone Treatment for Postpartum Cocaine Users”

11/6/ 2013: Perinatal Mental Health Conference Sponsored by NIMH, Chicago Illinois, Symposium Chair and Speaker, Substance Abuse in Childbearing Women

3/4/ 2013: 5th World Conference on Women’s Mental Health, Lima, Peru “Symptom Onset Antidepressant Treatment for Premenstrual Dysphoric Disorder”

3/6/2009: American Psychopathological Association Annual Meeting, New York, New York, “Integration of Gender Issues into DSM 5”

9/20/2008: World Psychiatric Association, Prague, Czech Republic, “Update on Gender Issues in DSM 5”

5/21-26/2005: American Psychiatric Association, American Psychiatric Association Annual Meeting, Atlanta, GA, “Sex Differences in the Course and Treatment of Psychiatric Conditions”

3/18/2004: International Association for Women’s Mental Health, Marriot Wardman Park, Washington, D.C., “Depression and Anxiety in Women”

**Professional Service**:

**Peer Review Groups/Grant Study Sections:**

2016 Ad Hoc Program Reviewer, NIH and ORWH SCORs on Sex Differences

2015 Ad Hoc Reviewer, NIMH, Effectiveness & Services R01 SEP

2014 Ad Hoc Reviewer, NIH Clnical Center Collaborations with NIH Intramural/ Extramural Researchers

2013 Ad Hoc Reviewer, NIH Clnical Center Collaborations with NIH Intramural/ Extramural Researchers

2013 Ad Hoc Reviewer, Adult Psychopathology and Disorders of Aging Study Section

2012 Ad Hoc Reviewer, Interventions Committee for Adult Disorders

2012 NIH Special Review ZRG1 EMNR-Q (50) R: Specialized Centers of Research (SCOR) on Sex Differences

2009-2011 Chair, Adult Psychopathology and Disorders of Aging Study Section

2009-2011 Chair, NIH Biobehavioral and Behavioral Process Integrated Review Group, Collaborative Applications

2010 Ad Hoc Reviewer SEP ZMH1 ERB-B

2008-2009 Vice Chair, NIH Adult Psychopathology and Disorders of Aging Study Section

2008-2009 Vice Chair, NIH Biobehavioral and Behavioral Process Integrated Review Group, Collaborative Applications

2008 Ad Hoc Reviewer SEP ZMH1-ERB-P(02) F31/R36

2006-2008 Member, NIH Adult Psychopathology and Disorders of Aging Study Section

2006-2008 Member, NIH Biobehavioral and Behavioral Process Integrated Review Group, Collaborative Applications

2007 Ad Hoc Reviewer SNRS

2006 Ad Hoc Reviewer SEP-ERB-04

2006 Ad Hoc Reviewer B-START Review

2005 Ad Hoc Reviewer, NIH Psychiatric Services Review Study Section

2005 NIH Special Review, RFA, Centers for Women’s Health Research

**Journal Service:**

Editor/Associate Editor

2016-current Editorial Board, General Hospital Psychiatry

2007-2012 Editorial Board, General Hospital Psychiatry

2005-2010 Editorial Board, Women’s Health in Primary Care

2002-2007 Editorial Board, Maternal and Child Health Journal

2000-2005 Editorial Board, Archives of Women’s Health

2000-2002 Editor, Special Section on Anxiety Disorders, Psychiatric Services

Reviewer

1993 –current Reviewer for: American Journal of Psychiatry, Archives of Women’s Health, Biological Psychiatry, Depression and Anxiety, Journal of Clinical Psychiatry, Neuropsychopharmacology, New England Journal of Medicine, Psychiatric Services, Psychosomatic Medicine, JAMA Psychiatry, Lancet, Lancet Psychiatry, Psychoneuroendocrinology, Journal of Clinical Psychopharmacology, Journal of Affective Disorders, Journal of Nervous and Mental Disease, Obstetrics and Gynecology, European Journal of Obstetrics and Gynecology, Journal of the American Medical Association

**Professional Organizations:**

 **American Psychiatric Association**

2014- Steering Committee member, DSM 5

2013-2014 Planning Committee member, DSM 5

2007-2012 Chair, DSM 5 Sub-workgroup on Premenstrual Dysphoric Disorder

2007-2012 Chair, Gender and Culture Study group for DSM 5

2006-2012 DSM 5 Task Force Member, General Steering Workgroup

2006-2010 Chair, Joint ACOG and APA Committee on Management of Depression In Pregnancy

2004-2006 APA, Associate Editor, Handbook on Psychiatric Measures, Revised

2003-2005 DSM 5 Planning Group, Section on Women’s Mental Health Issues

1998-2000 APA, Principal Contributor to Mood Disorders Chapter, Handbook on Psychiatric Measures

1998-1999 APA Council on Medical Education & Career Development Planning, Subcommittee on Self-Assessment Exams

1995-1997 American Psychiatric Association, Committee on Women

**American Board of Psychiatry and Neurology**

1993-1999 Board Examiner, American Board of Psychiatry & Neurology

**New Clinical Drug Evaluation Unit/ American Society of Clinical Psychopharmacology**

2011-2015 Member, Program Committee

**North American Society for Psychosocial Obstetrics and Gynecology**

2007-2009 President

2005-2007 Treasurer

2000-2006 Member, Membership Committee

2000-2001 Program Co-Chair

1998-2003 Trustee-At-Large

**International Association of Women’s Mental Health**

2004-2008 Secretary

**Society for Biological Psychiatry**

2005-2007 Member, Program Committee

1996-2000 Member, Membership Committee

1995-1998 Member, Program Committee

**American College of Neuropsychopharmacology**

2016- Member

**Consultative Positions**

1. Consultant, Centers for Disease Control, Expert Meeting on Perinatal Substance Abuse
2. Consultant, Centers for Disease Control, Expert Meeting on Perinatal Use of Antidepressants

2011-12 Consultant, Technical Expert Panel, AHRQ/Duke Comparative Effectiveness Review: Efficacy and Safety of Screening for Postpartum Depression

1. Consultant, Surgeon General’s Workshop on Women’s Mental Health
2. Consultant, Secretary’s Advisory Commission on Infant Mortality
	1. Consultant, Federal Healthy Start Initiative

**Yale University Service**

2011-2012 Member, Search Committee for Chair of Obstetrics, Gynecology & Reproductive Sciences

2010-2012 Reviewer, McKern Fellowship Committee

2009-2012 Member, Allotment Committee

2009-Current Member, Tenured Faculty Committee, Department of Psychiatry

2014- Member, Senior Appointments and Promotion Committee

2016- Member, Medical Student Thesis Awards Committee

**Thesis/Dissertation Committees at Yale University**

2014-2015 Chair, Thesis Committee for Regina Melendez Quesada, Doctoral Candidate, Yale School of Medicine

2011-2012 Chair, Dissertation Committee for Anita Sung, Doctoral Candidate

 Epidemiology and Public Health

2011-2012 Chair, Thesis Committee for Odayme Quesada, Doctoral Candidate, Yale School of Medicine

2011-2012 Member, Dissertation Committee for Heather Cole-Lewis, Doctoral Candidate, Epidemiology and Public Health

2007-2008 Chair, Thesis Committee for Lori Spoozak, Doctoral Candidate, Yale School of Medicine

2005-2006 Chair, Thesis Committee for Shari Rogal, Doctoral Candidate, Yale School of Medicine

 And Masters Candidate Epidemiology and Public Health

2005-2006 Chair, Thesis Committee for Aizza Hassan, Masters Candidate, Epidemiology and Public Health

**Thesis/Dissertation Committees Outside Yale University**

2006-2007 Member, Dissertation Committee for Megan Smith, Doctoral Candidate, Boston University Department of Epidemiology and Public Health

2005-2006 Member, Dissertation Committee for Mary Cavaleri, Doctoral Candidate, New York University

2001-2002 Member, Dissertation Committee for Lori Ross, Doctoral Candidate, McMaster University

**Public Service**

2016- Secretary, Temple B’Nai Chaim, Redding, CT

2010-2015 Trustee at Large, Temple B’Nai Chaim, Redding, CT

2010-Current Elected Member, Redding Board of Finance, Redding, CT

2010 Connecticut Psychiatric Society Task Force on Women

2009 State Perinatal Depression Screening Work Group

* 1. Member, New Haven Healthy Start Community Consortium

**Bibliography:** Peer-reviewed original research

1. Donner DD, **Yonkers KA**: Hormone induced conformational changes in the hepatic insulin receptor. *Journal of Biological Chemistry* 1986; 258 (15): 9413-9418.
2. **Yonkers KA**, Ellison J, Shera D, Pratt L, White K, Cole, JO Peterson LJ, Samuelson H, Keller MB: Pharmacotherapy observed in a large longitudinal study on anxiety disorders. *Psychopharmacology Bulletin* 1992; 28(2): 131-137.
3. **Yonkers KA** and White K: Premenstrual exacerbation of depression: One process or two? *Journal of Clinical Psychiatry*. 1992; 53: 289-292.
4. Fierman EJ, Hunt MF, Pratt LA, Warshaw MG, **Yonkers KA**, Peterson LG, Epstein-Kaye TM, Norton HS: Trauma and posttraumatic stress disorder in subjects with anxiety disorders. *American Journal of Psychiatry* 1993;150(12):1872-1874.
5. Warshaw MG, Fierman E, Pratt L, Hunt M, **Yonkers KA**, Massion AO, Keller MB: Quality of life and dissociation in anxiety disorder patients with trauma histories or PTSD. *American Journal of Psychiatry 1*993;150(10):1512-1516.
6. Reich J, Warshaw M, Peterson LG, White K, Keller MB, Lavori PW, **Yonkers KA**: Comorbidity of panic and major depressive disorder. *Journal of Psychiatric Research* 1993:27(1):23-33.
7. Keller MB, **Yonkers KA**, Warshaw MG, Pratt LA, Gollan JK, Massion AO, White K, Swarta AR, Reich J, Lavori PW: Remission and relapse in subjects with panic disorder and panic with agoraphobia: A prospective short-interval naturalistic follow-up. *The Journal of Nervous and Mental Disease* 1994;182(5):290-296.
8. Armitage R, **Yonkers KA**: Case report: Menstrual-related very short REM latency in a healthy normal control. *Sleep* 1994;17(4):345-347.
9. Rogers MP, White K, Warshaw MG, **Yonkers KA**, Rodriguez-Villa F. Chang, Keller MB: Prevalence of medical illness in patients with anxiety disorders. *The International Journal of Psychiatry in Medicine* 1994;24:83-97.
10. **Yonkers KA**, Gullion C, Williams A, Novak K, Rush AJ: Paroxetine as a treatment for premenstrual dysphoric disorder. *Journal of Clinical Psychopharmacology* 1996;16(1);3-8.
11. **Yonkers KA**, Elllison J, Shera D, Pratt LO, Cole JO, Fierman E, Keller MB, Lavori PW: Description of antipanic therapy in a prospective longitudinal study. *Journal of Clinical Psychopharmacology* 1996;16(3):223-232.
12. **Yonkers KA**, Warshaw MG, Massion AO, Keller MB: Phenomenology and course of generalized anxiety disorder. *The British Journal of Psychiatry* 1996;168:308-313.
13. Halbreich U, Petty F, **Yonkers KA**, Kramer GL, Rush AJ, Bibi KW: Low plasma γ-amino butyric acid levels during the late luteal phase of women with premenstrual dysphoric disorder. *American Journal of Psychiatry* 1996;153(5):718-720.
14. Goldenberg I, White K, **Yonkers K,** Reich J, Keller M: The infrequency of “pure culture” diagnoses among anxiety disorders. *Journal of Clinical Psychiatry* 1996; 57(11): 528-533.
15. **Yonkers KA**, Halbreich U, Freeman E, Brown C, Pearlstein T: Sertraline in the treatment of premenstrual dysphoric disorder. *Psychopharmacology Bulletin* 1996;32(1):41-46.
16. Shelton RC, Davidson J, **Yonkers KA**, Koran L, Thase ME, Pearlstein T, Halbreich U: The undertreatment of dysthymia. *Journal of Clinical Psychiatry* 1997; 58(2): 59-65.
17. Armitage R, **Yonkers K**, Cole D, Rush AJ. A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients. *Journal of Clinical Psychopharmacology* 1997;17:161-168.
18. **Yonkers KA**, Halbreich U, Freeman E, Brown C, Endicott J, Frank E, Parry B, Pearlstein T, Severino S, Stout A, Stone A, Harrison W, The Sertraline Premenstrual Dysphoric Collaborative Study Group: Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. *Journal of the American Medical Association* 1997;278(12):983-988.
19. **Yonkers KA**, Zlotnick C, Allsworth J, Warshaw M, Shea T, Keller MB: Is the course of panic disorder the same in women and men. *The American Journal of Psychiatry*, 1998;155:596-602.
20. Rush AJ, Armitage R, Gillin JC, **Yonkers KA**, Winokur A, Moldofsky H, Vogel GW, Kaplita SB, Fleming JB, Montplaisir J, Erman MK, Albala BJ, McQuade RD. Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. *Biological Psychiatry* 1998;44:3-14.
21. Gurguis GNM, **Yonkers KA**, Phan SP, Blakeley JE, Williams A, Rush AJ. Adrenergic receptor function in late luteal phase dysphoric disorder. I. Platelet membrane alpha2 receptors: coupling to Gi protein, effect of phase of menstrual cycle and the predictive value of binding indices. *Psychiatry Research* ; 1998; 79:31-42.
22. Gurguis GNM, **Yonkers KA** Blakeley JE, Phan SP, Rush AJ. Adrenergic receptors in premenstrual dysphoric disorder: II. Neutrophil β2-adrenergic receptors: Gs protein coupling, phase of menstrual cycle and prediction of luteal phase symptom severity, *Biological Psychiatry*; 1998;44:600-609.
23. Leibenluft, E., Ashman, S.B., Feldman-Naim S., **Yonkers, KA**. Lack of relationship between menstrual cycle phase and mood in women with rapid cycling bipolar disorder, *Biological Psychiatry,* 1999;46:577-580.
24. Kornstein SG, Schatzberg AF, Thase ME, **Yonkers KA**, McCullough JP, Keitner GI, Gelenberg AJ, Ryan CE, Hess AL, Harrison W, Davis SM, Keller MB. Gender differences in chronic major and double depression, *Journal of Affective Disorders*, 2000; 60(1), 1-11.
25. **Yonkers KA**, Dyck I, Warshaw M, Keller MB. Factors predicting the clinical course of generalized anxiety disorder. *British Journal of Psychiatry*, 2000; 176: 544-550.
26. Kornstein SG, Schatzberg AF, Thase ME, **Yonkers KA**, McCullough JP, Keitner GI, Gelenberg AJ, Davis SM, Keller MB. Gender differences in treatment response to sertraline versus imipramine in chronic depression, *American Journal of Psychiatry*, 2000; 157:1445-1452.
27. Pearlstein TB, Halbreich U, Batzar ED, Brown CS, Endicott J, Frank E, Freeman EW, Harrison WM, Haskett RF, Stout AL, **Yonkers KA**. Psychosocial Functioning in Women with Premenstrual Dysphoric Disorder Before and After Treatment with Sertraline or Placebo. Journal *of Clinical Psychiatry*, 2000; 61: 101-109.
28. **Yonkers KA**, Dyck IR, Keller MB: An eight year longitudinal comparison of clinical course and characteristics of social phobia among men and women. *Psychiatric Services*, 2001; 52(5):637-643.
29. **Yonkers KA**, Ramin SM, Rush AJ, Navarrette CA, Carmody T, March D, Heartwell SF, Leveno KJ: Presence and persistence of postpartum depression in an inner-city maternal health system. *American Journal of Psychiatry*, 2001; 158: 1856-1863.
30. Freeman, E, Rickels K, **Yonkers KA**, Kunz N, McPherson M: Venlafaxine in the Treatment of Premenstrual Dysphoric Disorder. *Obstetrics & Gynecology*, 2001; 98 (5), 737-744.
31. Rapaport MH, Judd LL, Schettler PJ, **Yonkers KA**, Thase ME, Kupfer DJ, Frank E, Plewes JM, Tollefson GD, Rush AJ: A descriptive analysis of minor depression. *American Journal of Psychiatry*, 2002; 159 (4): 637-643.
32. Halbreich U, Bergeron R, **Yonkers KA**, Freeman E, Stout AL, Cohen L. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. *Obstetrics & Gynecology*, 2002; 100: 1219-1229.
33. **Yonkers KA**, Bruce SE, Dyck IR, Keller MB: Chronicity, Relapse and Illness, Course of Panic Disorder, Social Phobia and Generalized Anxiety Disorder: Findings in Men and Women from 8 Years of Follow Up, *Depression and Anxiety*, 2003, 17: 173-179.
34. Borenstein JE, Dean B, Endicott J, Wong J, Brown C, Dickerson V, **Yonkers KA**. The Health and economic impact of premenstrual syndrome. *The Journal of Reproductive Medicine*, 2003; 48 (7): 515-524.
35. **Yonkers KA**, Pearlstein T, Rosenheck R. Premenstrual disorders: Bridging research and clinical reality. *Archives of Women’s Mental Health*, 2003; 6 (4); 287-292.
36. Smith M, Cavaleri MA, Howell HB, Poschman K, Rosenheck RA, **Yonkers KA**: Screening for and detection of depression, panic disorder and PTSD in public sector obstetrical clinics. *Psychiatric Services*, 2004; 55 (4): 407-414.
37. Judd LJ, Rapaport MH, **Yonkers KA**, Rush AJ, Frank E, Thase ME, Kupfer DJ, Plewes JM, Schettler PJ, Tollefson G: Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder. The *American Journal of Psychiatry*, 2004; 161 (10): 1864-1871.
38. Perkonigg A, **Yonkers KA**, Pfister H, Lieb R, Wittchen H-U. Risk factors for premenstrual dysphoric disorder in a community sample of young women: The role of traumatic events and posttraumatic stress disorder. *The Journal of Clinical Psychiatry*, 2004; 65 (10): 1314-1322.
39. Cohen LS, Soares CN, **Yonkers KA**, Bellew KM, Bridges IM, Steiner M. Paroxetine controlled release for premenstrual dysphoric disorder: A double-blind, placebo-controlled trial. *Psychosomatic Medicine*, 2004; 66 (5): 707-713.
40. **Yonkers KA**, Pearlstein T, Fayyad R, Gillespie JA: Luteal phase treatment of premenstrual dysphoric disorder (PMDD) improves symptoms that continue into postmenstrual phase. *Journal of Affective Disorders*, 2005; 85 (3): 317-321.
41. Pearlstein T, **Yonkers KA**, Fayyad R, Gillespie JA: Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. *Journal of Affective Disorders*, 2005; 85: 275-282.
42. Bruce SE, **Yonkers KA**, Otto MW, Eisen JL, Weisberg RB, Pagano M, Shea MT, Keller MB: Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study, *Am Journal of Psychiatry,* 2005;162 (6):1179-87.
43. **Yonkers KA**, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a New Low-Dose Oral Contraceptive With Drospirenone in Premenstrual Dysphoric Disorder. *Obstetrics & Gynecology*, 2005 106: 492-501.
44. Pearlstein T, Bachmann GA, Zacur HA, **Yonkers, KA**. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. *Contraception*, 2005; 73: 414- 421.
45. Smith MV, Poschman, KP, Allen AA, Cavaleri MA, Howell HB, **Yonkers KA**. Symptom
Profiles of PTSD in Pregnancy. *American Journal of Psychiatry,* 2006, 163, pp 881-884.
46. **Yonkers KA**, Holthausen GA, Poschman K, Howell HB. Symptom onset treatment for women with premenstrual dysphoric disorder. *Journal of Clinical Psychopharmacology*. 2006, 26:198-202.
47. Dean BB, Borenstein JE, Knight K and **Yonkers KA**: Evaluating the Criteria Used for the Identification of PMS, *Journal of Women’s Hea*lth. 2006, 15 (5):546-555.
48. Borenstein JE, Dean BB, Yonkers **KA**, Endicott J. Using the daily record of severity of problems as a screening instrument for premenstrual syndrome, Obstetrics & Gynecology. 2007, 109 (5):1068-75.
49. Rogal S, Poschmann K, Belanger K, Howell H, Smith MV, Medina J, **Yonkers KA**:Effects of posttraumatic stress disorder on pregnancy outcomes*. Journal of Affective Disorders.* 2007, 107: 137-143.
50. Borenstein JE, Dean BB, Leifke E, Korner P, **Yonkers KA**. Differences in symptom scores and health outcomes in premenstrual syndrome. *Journal of Women's Health.* 2007;16:1139-44.
51. Kessler RC, Gruber M, Hettema JM, Hwang I, Sampson N, **Yonkers KA**. Co-morbid major depression and generalized anxiety disorders in the National Comorbidity Survey follow-up. *Psychological Medicine.* 2008; 38:365-74.
52. Wallenstein GV, Blaisdell-Gross B, Gajria K, Guo A, HM, Kornstein SG, **Yonkers KA.** Development and validation of the Premenstrual Symptoms Impact Survey (PMSIS): a disease-specific quality of life assessment tool. *Journal of Women's Health*. 2008;17(3):439-50.
53. Bernstein IH, Rush AJ, **Yonkers KA,** Carmody TJ, Woo A, McConnell K, Trivedi MH. Symptom features of postpartum depression: are they distinct? *Depression & Anxiety.* 2008, 25(1):20-26.
54. Hine CE, Howell HB, **Yonkers KA**. Integration of medical and psychological treatment within the primary health care setting. *Social Work in Health Care.* 2008, 47(2):122-134.
55. **Yonkers KA**, Lin H, Howell HB, Heath AC, Cohen LS. Pharmacologic treatment of postpartum women with new-onset major depressive disorder: a randomized controlled trial with paroxetine. *Journal of Clinical Psychiatry.* 2008, 69(4):659-665.
56. Spoozak L, Gotman N, Smith MV, Belanger K, **Yonkers KA**. Evaluation of a social support measure that may indicate risk of depression during pregnancy. *Journal of Affective Disorders.* 2009, 114(1-3):216-223.
57. Smith MV, Shao L, Howell H, Wang H, Poschman K, **Yonkers KA**. Success of mental health referral among pregnant and postpartum women with psychiatric distress. *General Hospital Psychiatry.* 2009, 31(2):155-162.
58. **Yonkers KA**, Smith MV, Lin H, Howell HB, Shao L, Rosenheck RA. Depression screening of perinatal women: evaluation of the Healthy Start Depression Initiative. *Psychiatric Services.* 2009,60(3):322-328.
59. Lancaster GI, O'Connell R, Katz DL, Manson JE, Hutchison WR, Landau C, **Yonkers KA**, Healthcare Professionals for Healthcare R, Lancaster GI, O'Connell R, Katz DL, Manson JE, Hutchison WR, Landau C, Yonkers KA. The expanding medical and behavioral resources with access to care for everyone health plan. *Annals of Internal Medicine* 2009;150:490-2.
60. **Yonkers KA,** Howell H, Allen A, Ball S, Pantolon M, Rounsaville B. A treatment for substance abusing pregnant women. *Archives of Women's Mental Health.* 2009; 12(4): 221-227.
61. **Yonkers KA,** Smith MV, Gotman N, Belanger K. Typical somatic symptoms of pregnancy and their impact on a diagnosis of major depressive disorder *General Hospital Psychiatry.* 2009; 31(4):327-33.
62. Smith MV, Gotman N, Lin H, **Yonkers KA**. Do the PHQ-8 and the PHQ-2 Accurately Screen for Depressive Disorders in a Sample of Pregnant Women? *General Hospital Psychiatry.* 2010;32(5):544-8.
63. **Yonkers KA**, Gotman, N, Kershaw, T, Forray, A, Howell, HB, Rounsaville, BJ. Screening for Prenatal Substance Use: Development of the Substance Use Risk Profile-Pregnancy Scale. *Obstetrics & Gynecology*, 2010, 116(4):827-33.
64. Smith MV, Shao L, Lin H, Howell H, **Yonkers KA**. Perinatal depression and birth outcomes in a Healthy Start project. *Maternal and Child Health Journal.* 2011; 15:401-409.
65. Buist A, Gotman N, **Yonkers KA**. Generalized anxiety disorder: Course and risk factors in pregnancy. *Journal of Affective Disorders*, 2011 131(1-3):277-83. PMCID: 3095713
66. **Yonkers KA**, Howell HB, Gotman N, Rounsaville BJ. Self-report of illicit substance use versus urine toxicology results from at-risk pregnant women. *Journal of Substance Use*, 2011;16 (5): 372-380.
67. **Yonkers KA,** Gotman N, Smith MV , Forray A, Belanger K, Brunetto W, Lin H, Burkman RT, Zelop CM, Lockwood CJ. Does Antidepressant Use Attenuate The Risk Of A Major Depressive Episode In Pregnancy**?**  *Epidemiology,* 2011:22; 848-854. PMCID: 3188383
68. Hartlage SA, Freels SA, Gotman N, **Yonkers KA.** Criteria for Premenstrual Dysphoric Disorder (PMDD): Secondary Analyses of Relevant Data Sets. *Archives of General Psychiatry*. 2012;69(3):300-305. PMCID:3370334
69. Quesada O, Gotman N, Howell HB, Funai E, Rounsaville BJ, **Yonkers KA.** Prenatal Hazardous Substance Use and Adverse Birth Outcomes, *Journal of Maternal, Fetal and Neonatal Medicine, 2012: 25; 1222-1227*.
70. Epperson CN, Steiner M, Hartlage SA, Eriksson E, Schmidt PE, Jones I, **Yonkers KA**. Premenstrual Dysphoric Disorder: Evidence for a New Category for the DSM-5. *American Journal of Psychiatry*, 2012: 169(5); 465-475. PMCID: 3462360
71. **Yonkers KA,** Norwitz ER, Smith MV , Lockwood CJ, Gotman N, Lin H, Luchansky E, Belanger K. Major depressive disorder and serotonin reuptake inhibitor treatment as risk factors for preterm birth. Epidemiology, 2012: Vol 23 (5): 677-685. PMCID: 3415566
72. **Yonkers KA,** Forray A, Howell HB, Gotman N, Kershaw T, Rounsaville BJ, Carroll KM. Motivational Enhancement Therapy Coupled with Cognitive Behavioral Therapy versus Brief Advice; A Randomized Trial for Treatment of Hazardous Substance Use in Pregnancy and After Delivery. *General Hospital Psychiatry.* 2012: 34 (5): 439-449.
73. Smith MV, Sung A, Shah B, Mayes L, Klein DS, **Yonkers KA.** Neurobehavioral assessment of infants born at term and in utero exposure to serotonin reuptake inhibitors.2012. *Early Human Development.*89(2):81-86.
74. **Yonkers KA,**Pearlstein TB, Gotman N. A pilot study to compare fluoxetine, calcium, and placebo in the treatment of premenstrual syndrome. J Clinical Psychopharmacololgy, 2013, Vol 33 (5); 614-620.
75. Rakofsky JJ, Schettler PJ, Kinkead BL, Frank E, Judd LL, Kupfer DJ, Rush AJ, Thase ME, **Yonkers KA**, Rapaport MH. The Prevalence and Severity of Depressive Symptoms along the Spectrum of Unipolar Depressive Disorders: A Post-hoc Analysis. Journal of Clinical Psychiatry. 2013. Vol 74: 1084-1089.
76. Cole-Lewis H, Kershaw TS, Earnshaw VA, **Yonkers KA**, Ickovics JR. Pregnancy-specific stress, preterm birth and gestational age among high-risk young women. Health Psychology, 2014, (Epubl ahead of print).
77. Hartlage SA, Breaux C, **Yonkers KA.** Addressing Concerns about the Inclusion of Premenstrual Dysphoric Disorder (PMDD) in the DSM-5. Journal of Clinical Psychiatry, 2014, Vol 75 (1):70-76.
78. Huang H, Coleman S, Bridge JA, **Yonkers KA**, Katon W. A meta-analysis of the relationship between atnidepressant use in pregnancy and the risk of preterm birth and low birth weight. *General Hospital Psychiatary*.2014:36: 13-18.
79. Forray A, Gotman N, Kershaw T, **Yonkers KA.** Perinatal smoking and depression in women with concurrent substance use. *Addictive Behaviors,* 2014, Vol 39 (4):749-756.
80. **Yonkers KA**, Smith MV, Forray A, Epperson CN, Costello D, Lin H, Belanger K. Pregnant women with posttraumatic stress disorder and risk of preterm birth. JAMA Psychiatry, 2014; 71:897-904.
81. **Yonkers KA**, Forray A, Nich C, Carroll KM, Hine C, Merry BC, Shaw H, Shaw J, Sofuoglu M. Progesterone for the reduction of cocaine use in post-partum women with a cocaine use disorder: a randomised, double-blind, placebo-controlled, pilot study. *The Lancet Psychiatry* 2014;1:360-367. PMC4199242
82. Smith M, Costello D, **Yonkers KA**. Clinical Correlates of Prescription Opioid Analgesic Use in Pregnancy. *Maternal and Child Health Journal,* 2014:1-9. PMC4272915
83. Forray F, Merry B, Lin H, Prah-Ruger J, Yonkers KA. Perinatal substance use: A prospective evaluation of abstinence and relapse. *Drug and Alcohol Dependence, 2015*; 150:147-155.
84. **Yonkers KA,** Kornstein SG, Gueorguieva R, Merry B, Van Steenburgh K, Altemus M. Symptom-onset dosing of sertraline for the treatment of premenstrual dysphoric disorder: A multi-site, double-blind, randomized, placebo-controlled trial. *JAMA Psychiatry,* 2015; 72: 957-1064.
85. Gariepy AM, Lundsberg LS, Stolar M, Stanwood NL, **Yonkers KA.** Are pregnancy planning and timing associated with preterm or small for gestational age births? *Fertil Steril* 2015;104:1484-1492.
86. Smith MV, Gotman N, **Yonkers KA**. Early Childhood Adversity and Pregnancy Outcomes. Matern Child Health J. 2016.
87. Gariepy AM, Lundsberg LS, Miller D, Stanwood NL, **Yonkers KA.** Are pregnancy planning and pregnancy timing associated with maternal psychiatric illness, psychological distress and support during pregnancy? J Affect Disord. 2016;205:87-94. PMCID: PMC5048515.
88. **Yonkers KA**, Cameron B, Gueorguieva R, Altemus M, Kornstein SG. The Influence of Cyclic Hormonal Contraception on Expression of Premenstrual Syndrome. J Womens Health (Larchmt). 2016. Epub 2016/11/18. doi: 10.1089/jwh.2016.5941. PubMed PMID: 27854559.
89. Wright TE, Terplan M, Ondersma SJ, Boyce C, **Yonkers K**, Chang G, Creanga AA. The role of screening, brief intervention, and referral to treatment in the perinatal period. American Journal of Obstetrics and Gynecology. 2016;215(5):539-47. doi: <http://dx.doi.org/10.1016/j.ajog.2016.06.038>.

Reviews (Peer-Reviewed)

1. **Yonkers KA**, Kando J, Cole JO, Blumenthal SL: Gender differences in the pharmacokinetics and pharmacodynamics of psychotropic agents. *American Journal of Psychiatry* 1992; 149 (5): 587-595.
2. Severino SK, **Yonkers KA**: A literature review of psychotic symptoms associated with the premenstruum. *Psychosomatics* 1993;34(4):299-306.
3. **Yonkers KA**: Panic disorder in women. *Journal of Women's Health* 1994;3(6):481-486.
4. Kando JC, **Yonkers KA**, Cole JO: Gender as a risk factor for adverse events to medications. *Drugs* 1997;50(1):1-6.
5. **Yonkers KA**, Little BB. Lithium use during pregnancy. *CNS Drugs* 1998; 9:261-269.
6. **Yonkers KA**, Panic Disorder: Are there meaningful differences? *Journal of the American Medical Women’s Association* 1998;53 (4):161-164.
7. **Yonkers KA**, Brawman-Mintzer O. The Pharmacological Treatment of Depression: Is Gender A Critical Factor? *Journal of Clinical Psychiatry* 2002; 63 (7): 610-615.
8. Pearlstein T, **Yonkers KA**: Review of fluoxetine and its clinical applications in premenstrual dysphoric disorder. *Expert Opinion in Pharmacotherapy*, 2002; 3 (7), 979-991.
9. Altshuler L, Richards M, **Yonkers KA**: Treating bipolar disorder during pregnancy, *Current Psychiatry*, 2003; 2(7):14-26.
10. Steiner M, **Yonkers KA**: Evidence-based treatment of mood disorders in women, *Mental Fitness*, 2003; 2(3): 34-67.
11. **Yonkers KA**, Smith M, Brunetto WL, Cavaleri MA: Recognizing depression in gynecologic patients. *Contemporary Obstetrics and Gynecology*, 2004; 49 (6).
12. **Yonkers KA**, Wisner K, Stowe Z, Leibenluft E, Cohen L, Miller L, Manber R, Viguera A, Suppes T, Altshuler L. Management of bipolar disorder during pregnancy and the postpartum period. *American Journal of Psychiatry*, 2004; 161(4) :608-620.
13. Smith M, Brunetto WL, **Yonkers KA**: Identifying perinatal depression--sooner is better. *Contemporary Obstetrics and Gynecolog*y, 2004; 49 (4).
14. Halbreich U, Backstrom T, Eriksson E, O'Brien S, Calil H, Ceskova E, Dennerstein L, Douki S, Freeman E, Genazzani A, Heuser I, Kadri N, Rapkin A, Steiner M, Wittchen HU. Yonkers **KA.** Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. Gynecological Endocrinology, 2007, 23 (3):123-130.
15. **Yonkers KA,** O’Brien PMS and Eriksson E: An Update on the Pathophysiology and Treatment of Premenstrual Dysphoric Disorder. *Lancet*, 2008, Vol 371, pp 1200-1204.
16. Cunningham J, Eriksson E, O’Brien PMS, **Yonkers KA**, *Harvard Review of Psychiatry*. 17(2):120-37, 2009.
17. **Yonkers KA,** Wisner KL, Stewart DE, Oberlander TF, Dell DL, Stotland N, Ramin S, Chaudron L, Lockwood CJ. The Management of depression during pregnancy: A report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. *Obstetrics & Gynecology.* 114(3):703-13, 2009 Sep.
18. **Yonkers KA**, Vigod S, Ross L. Clinical Expert Series: Diagnosis and management of mood disorders in pregnant and postpartum women. *Obstetrics and Gynecology.*117 (4): 961-977, 2011.
19. Nevatte T, O'Brien PM, Backstrom T, Brown C, Dennerstein L, Endicott J, Epperson CN, Eriksson E, Freeman EW, Halbreich U, Ismail K, Panay N, Pearlstein T, Rapkin A, Reid R, Rubinow D, Schmidt P, Steiner M, Studd J, Sundstrom-Poromaa I, **Yonkers K**, Consensus Group of the International Society for Premenstrual D. ISPMD consensus on the management of premenstrual disorders. *Archives of Women's Mental Health*;2014;16:279-291.
20. Coughlin CG, Blackwell KA, Bartley C, Hay M, **Yonkers KA**, Block MH. Obstetrical and neonatal outcomes following antipsychotic medication exposure in pregnancy. *Obstetrics & Gynecology*; 2015, Vol 125 (5); 1224-35.
21. Martino S, Zimbrean P, Forray A, Kaufman J, Desan P, Olmstead TA, Gueorguieva R, Howell H, McCaherty A, **Yonkers KA**. See One, Do One, Order One: a study protocol for cluster randomized controlled trial testing three strategies for implementing motivational interviewing on medical inpatient units. *Implementation science : IS* 2015;10:138

Editorials, Reviews (non-Peer Reviewed), Chapters, Books

1. **Yonkers KA**, Hamilton JA: Psychotropic medications: Issues for use in women. In: Weissman MM, Riba M (Eds.). American Psychiatric Press Review of Psychiatry, Volume 14, American Psychiatric Press, Washington, D.C., pp.147-178, 1995.
2. Hamilton JA, **Yonkers KA**: Managing Medication. In: The Women's Complete Healthbook, Chapter 39, American Medical Women's Association, The Philip Lief Group, Inc., New York, NY, 1995.
3. Cole JO, **Yonkers KA**: Nonbenzodiazepine Anxiolytics. In: The American Psychiatric Press Textbook of Psychopharmacology, Chapter 12, American Psychiatric Press, Washington, D.C., pp.193-209, 1995.
4. **Yonkers KA**, Gurguis G: Gender Differences in the Prevalence and Expression of Anxiety Disorders. In: Seeman, MV (Ed) Gender and Psychopathology, Chapter 6, American Psychiatric Press, Washington, D.C., pp.113-130.
5. **Yonkers KA**, Cunningham FG: Psychiatric disorders complicating pregnancy. In: Cunningham FG, MacDonald PC, Gant NF, Leveno KJ, Gilstrap LC (Eds.), Williams Obstetrics, 19th Edition, Supplement No. 3, Appleton & Lange: Norwalk, CT, pp.1-15, 1993.
6. Hamilton JA, **Yonkers KA**: Sex differences in the pharmacokinetics of psychotropic medications. Part I: Physiological basis for effects. In: Jensvold MH, Halbreich U, Hamilton JA (Eds.) Psychopharmacology of Women: Sex Gender and Hormonal Considerations, Volume 1, 1st Edition, Chapter 2, American Psychiatric Press, Washington, D.C., 1996.
7. **Yonkers KA**, Hamilton JA: Sex differences in pharmacokinetics of psychotropic medications. Part II: Effects on selected psycho tropics. In: Jensvold MH, Halbreich U, Hamilton JA (Eds.). Psychopharmacology of Women: Sex, Gender and Hormonal Considerations Volume 1, 1st Edition, Chapter 3, American Psychiatric Press, Washington, 1996.
8. **Yonkers KA**, Ellison JM: Anxiety disorders in women and their pharmacologic treatment. In: Jensvold MH, Halbreich U, Hamilton JA (Eds.). Psychopharmacology of Women: Sex, Gender and Hormonal Considerations Volume 1, 1st Edition, Chapter 13, American Psychiatric Press, Washington, D.C., 1996.
9. **Yonkers KA**, Bradshaw KD: Psychological Factors and Infertility. In: Bradshaw KD (Ed) Infertility and Reproductive Medicine. Clinics of North America, 2nd edition, Vol. 8, W.B. Saunders Company, Philadelphia, PA, pp. 305-319, 1997.
10. **Yonkers KA**, Clark RH, Trivedi MH. The psychopharmacological treatment of non-major mood disorders. In: Rush AJ (Ed) Mood Disorders. Systematic Medication Management. Modern Problems of Pharmacopsychiatry. II Series, Vol. 25, Karger Medical and Scientific Publishers, Basel, Germany, pp 146-166, 1997.
11. Kando JC, **Yonkers KA**. Relevant sex differences in the prescribing and monitoring of psychotropic medications. In: Dunner DL, Rosenbaum JF (eds). The Psychiatric Clinics of North American Annual of Drug Therapy, Vol. 4, W.B. Saunders Company, Philadelphia, pp1-20, 1997.
12. **Yonkers KA**, Steiner M: Depression in Women Pocketbook, London, Martin Dunitz Ltd., 1998.
13. **Yonkers KA**, Bradshaw KA: Hormone Replacement and Oral Contraceptive Therapy: Do they induce or treat mood symptoms? Section I: Hormonal and Mood Disorders in Women. In: Leibenluft E, Riba M (Eds.). American Psychiatric Press Review of Psychiatry, Volume 18, American Psychiatric Press, Washington, D.C.,1999.
14. Ninan PT, Cole JO, **Yonkers KA**. Chapter 15. Nonbenzodiazepine anxiolytics. In: Textbook of Psychopharmacology, 2nd edition, American Psychiatric Press, Washington, D.C., pp287-300, 1998.
15. Steiner M, **Yonkers KA**, Eriksson E (eds): Mood Disorders in Women, London, Martin Dunitz Ltd., 2000.
16. **Yonkers KA**, Little B (eds): The Management of Psychiatric Illness in Pregnancy, Chapman Hall Ltd., 2000.
17. **Yonkers KA**, Davis LL: Premenstrual Dysphoric Disorder. In Comprehensive Textbook of Psychiatry, Seventh Edition, Lippincott Williams & Wilkins, Vol II, pp.1952-1958, 2000.
18. Howell H, Brawman-Mintzer O, Monnier J, **Yonkers KA**: Generalized Anxiety Disorder in Women, The Psychiatric Clinics of North America, Vol 24, pp.165-178, 2001.
19. March D, Pearlstein T, **Yonkers KA**: Treatment of Premenstrual Dysphoric Disorder, Psychiatric Clinics of North America: Annual of Drug Therapy, Vol 8, pp. 89-108, 2001.
20. **Yonkers KA**, Kidner CL: Sex Differences in Anxiety Disorders In Psychiatric Illness in Women. Edited by Lewis-Hall F, Williams T, Panetta J, Herrera J. Washington, D.C., American Psychiatric Publishing, 2002, pp 5-30.
21. Shim J, **Yonkers KA**: Sertraline. In Textbook of Psychopharmacology. Edited by Schatzberg A, Nemeroff C. Washington, D.C., American Psychiatric Press, 2004, pp247-258.
22. **Yonkers KA**, Brawman-Mintzer O: Women. In Handbook of Experimental Pharmacology: Antidepressants: Past, Present and Future, Volume 157, Chapter 13, 2004, pp 379-392.
23. National Institutes of Health State-of-the-Science Conference Statement: Cesarean delivery on maternal request, March 27-29, 2006. Obstetrics & Gynecology, 2006, 107(6):1386-1397.
24. **Yonkers KA**. Management of Depression and Psychoses in Pregnancy and the Puerperium. In: Creasy R, Resnik R, Iams J, Lockwood C, and Moore T (Eds), Maternal-Fetal Medicine, 6th Edition, Elsevier, Philadelphia, PA, 2007.
25. **Yonkers KA**, McCunn KL. Comorbidity of Premenstrual Syndrome and Premenstrual Dysphoric Disorder with other psychiatric conditions. In: Obrien S, Schmidt P, and Rapkin A (Eds), PMDD/PMS, 2007.
26. **Yonkers KA**, Spinelli M. Management of Depression During Pregnancy and the Puerperium. In: Tasman A, Kay J, Lieberman J, First M, Maj M (Eds), Psychiatry, 3rd Edition, John Wiley and Sons, Ltd, The Atrium, West Sussex, England, 2007.
27. **Yonkers KA.** The treatment of women suffering from depression who are either pregnant or breastfeeding. *American Journal of Psychiatry* 2007;164:1457-9.
28. **Yonkers KA**. Parsing risk for the use of selective serotonin reuptake inhibitors in pregnancy. *American Journal of Psychiatry*, 2009, 166(3):268-270. PMC4134929.
29. **Yonkers KA**. Management of Depression and Psychoses in Pregnancy and the Puerperium. In: Creasy R, Resnik R, Iams J, Lockwood C, and Moore T (Eds), Maternal-Fetal Medicine, 7th Edition, Elsevier, Philadelphia, PA, 2012.
30. **Yonkers KA.** The possible effects of depressive symptoms on risk of preterm birth are clouded by lack of control over confounding factors. *Evidence Based Medicine (BMJ),* 2013, Available on line Jan 17, 2013 10.1136/eb-2012-101136.
31. **Yonkers KA**, Blackwell KA, Glover J, Forray A. Antidepressant use in pregnant and postpartum women. Annual Review of Clinical Psychology, 2014, Vol 10: 369-92.

In Press

1. Lundsberg LS, Schwarz EB, Vilard N, **Yonkers KA,** Gariepy, AM. Clinical validation of PROMIS Global Short Form in pregnancy. In Press *Applied Research in Quality of Life.*

In Submission

1. Gariepy AM, Lundsberg LS, Vilardo N, Stanwood N, Yonkers DA, Schwarz EB. Pregnancy context and women’s health related quality of life. In resubmission, *Contraception.*
2. Loree A, Gariepy A, Prah Ruger J. Postpartum contraceptive use and rapid repeat pregnancy among women who use substances. In resubmission, *Substance Use and Misuse*